REGN Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 492 min ago

@ $951.18

Wydano: 3 geg. 2024 @ 21:01

Zwrot: 0.61%

Poprzedni sygnał: geg. 2 - 21:27

Poprzedni sygnał: Kupno

Zwrot: 1.79 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):
Our systems believe the stock currently is overvalued by 0.27% compare to its pairs and should correct downwards.

Stats
Dzisiejszy wolumen	525 885
Średni wolumen	472 833
Kapitalizacja rynkowa	103.71B
EPS	$0 ( 2024-05-02 )
Następna data zysków	( $10.09 ) 2024-06-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	27.52
ATR14	$28.38 (2.97%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Mccourt Marion	Sell	250	Common Stock
2024-05-01	Ryan Arthur F	Sell	3	Common Stock
2024-05-01	Ryan Arthur F	Sell	2	Common Stock
2024-05-01	Ryan Arthur F	Sell	7	Common Stock
2024-05-01	Ryan Arthur F	Sell	9	Common Stock

INSIDER POWER
-29.64
Last 100 transactions
Buy: 213 725 \| Sell: 393 182

Korelacja (AI algo v.1.1b): Overvalued: -0.27% $954.13 paired level. (Algorytm śledzi zmiany najbardziej skorelowanych akcji w czasie rzeczywistym i natychmiast aktualizuje)

Wolumen Korelacja

Długi: 0.89 (strong)

Krótki: -0.15 (neutral)

Signal:(58) Neutral

Regeneron Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
CFBK	0.904
NNBR	0.894
VTRS	0.875
PBPB	0.874
GANX	0.866
FTXH	0.862
IMTX	0.862
BKCC	0.859
FXCO	0.853
ARDX	0.848

10 Najbardziej negatywne korelacje
OSMT	-0.879
SVOK	-0.85
OPK	-0.847
SEV	-0.833
GHVI	-0.83
RAAC	-0.83
BFRI	-0.83
GOODM	-0.828
MLVF	-0.827
AMTI	-0.807

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Regeneron Pharmaceuticals Korelacja - Waluta/Towar

0.68
( moderate )

0.85
( strong )

-0.23
( neutral )

0.53
( weak )

0.29
( neutral )

-0.69
( moderate negative )

Regeneron Pharmaceuticals Finanse

Annual	2023
Przychody:	$13.12B
Zysk brutto:	$11.30B (86.16 %)
EPS:	$37.05

FY	2023
Przychody:	$13.12B
Zysk brutto:	$11.30B (86.16 %)
EPS:	$37.05

FY	2022
Przychody:	$12.17B
Zysk brutto:	$10.61B (87.18 %)
EPS:	$40.51

FY	2021
Przychody:	$16.07B
Zysk brutto:	$13.63B (84.83 %)
EPS:	$76.40

Financial Reports:

Symbol	Period	Year	Title
REGN	Q4	2023	Financial Report for REGN - Q4 2023

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.